Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

被引：41
|
作者：
Doebele, R. [1 ]
Ahn, M. [2 ]
Siena, S. [3 ,4 ]
Drilon, A. [5 ]
Krebs, M. [6 ]
Lin, C. [7 ]
De Braud, F. [8 ]
John, T. [9 ]
Tan, D. [10 ]
Seto, T. [11 ]
Dziadziuszko, R. [12 ]
Arkenau, H. [13 ]
Barlesi, F. [14 ]
Rolfo, C. [15 ]
Wolf, J. [16 ]
Chow-Maneval, E. [17 ]
Multani, P. [17 ]
Cui, N. [18 ]
Riehl, T. [18 ]
Cho, B. C. [9 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Seoul, South Korea
[3] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy
[4] Univ Milan, Milan, Italy
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA
[6] Univ Manchester, Manchester, Lancs, England
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[9] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[10] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[11] Natl Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[12] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland
[13] Sarah Cannon Res Inst, London, England
[14] Aix Marseille Univ, AP HM, Marseille, France
[15] Antwerp Univ Hosp, Oncol Dept, Phase 1 Early Clin Trials Unit, Antwerp, Belgium
[16] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Cologne, Germany
[17] Ignyta Inc, San Diego, CA USA
[18] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; entrectinib; ROS1 gene fusion;
D O I：
10.1016/j.jtho.2018.08.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA02.01
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [41] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
    Nguyen, Ly
    Monestime, Shanada
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
  • [42] Effect of race on the safety and efficacy of pemetrexed (P) therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC)
    Tai, D. F.
    Kulkarni, P.
    Wang, Y.
    Gill, J.
    Obasaju, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).
    Ou, Sai-Hong Ignatius
    Bang, Yung-Jue
    Camidge, D. Ross
    Riely, Gregory J.
    Salgia, Ravi
    Shapiro, Geoffrey
    Solomon, Benjamin J.
    Engelman, Jeffrey A.
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Tye, Lesley
    Wilner, Keith D.
    Stephenson, Patricia
    Varella-Garcia, Marileila
    Bergethon, Kristin
    Iafrate, Anthony John
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
    Lu, S.
    Chiu, C-H.
    Yu, Y.
    Loong, H. H. F.
    Lin, C. C.
    Hu, X.
    Dong, X.
    Li, J.
    Zhao, J.
    Ye-Hui, S.
    Zhang, Z.
    Zhao, N.
    Xia, J.
    Wang, D.
    Fan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S83 - S84
  • [45] MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Chu, P.
    Antoniou, M.
    Bhutani, M. K.
    Aziez, A.
    Daigl, M.
    VALUE IN HEALTH, 2019, 22 : S437 - S437
  • [46] A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets).
    Dingemans, Anne-Marie C.
    Griesinger, Frank
    Paz-Ares, Luis
    Perol, Maurice
    Ren, Shengxiang
    Hoglander, Elen
    Kurtsikidze, Nino
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Advances and future directions in ROS1 fusion-positive lung cancer
    Boulanger, Mary C.
    Schneider, Jaime L.
    Lin, Jessica J.
    ONCOLOGIST, 2024, 29 (11): : 943 - 956
  • [48] Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase- and ROS1 Fusion-Positive Non-Small Cell Lung Cancer in India
    Gupta, Dharna
    Gupta, Nidhi
    Singh, Navneet
    Prinja, Shankar
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [49] Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
    Bazhenova, L.
    Liu, S. V.
    Lin, J. J.
    Lu, S.
    Drilon, A.
    Chawla, S. P.
    Fakih, M.
    Krzakowski, M.
    Paz-Ares, L.
    Blakely, C.
    Buchschacher, G. L., Jr.
    Cassier, P.
    Fan, Y.
    Folprecht, G.
    McCallum, S.
    Pitcher, B.
    Chen, D.
    Freund, R.
    Springfeld, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S598 - S599
  • [50] Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib
    Choudhury, Noura J.
    Woo, Hyung Jun
    Chen, Monica
    Shah, Ronak
    Donoghue, Mark
    Berger, Michael
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2024, 8
12345